Christopher Gibson - 19 Dec 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
19 Dec 2025
Transactions value $
-$180,000
Form type
4
Filing time
19 Dec 2025, 17:04:55 UTC
Previous filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gibson Christopher Chief Executive Officer, Director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 19 Dec 2025 0001856369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Conversion of derivative security $0 +40,000 +4.38% $0 953,839 19 Dec 2025 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$180,000 -40,000 -4.19% $4.5 913,839 19 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Class B Common Stock Conversion of derivative security $0 -40,000 -0.84% $0 4,723,334 19 Dec 2025 Class A Common Stock 40,000 $0 Direct F1, F2
holding RXRX Class B Common Stock 386,000 19 Dec 2025 Class A Common Stock 0 $0 by LAHWRAN-3 LLC F1, F3
holding RXRX Class B Common Stock 388,000 19 Dec 2025 Class A Common Stock 0 $0 by LAHWRAN-4 LLC F1, F4
holding RXRX Class B Common Stock 50,000 19 Dec 2025 Class A Common Stock 0 $0 by Gibson Family Trust F1, F5
holding RXRX Stock Option (Right to Buy) 1,050,567 19 Dec 2025 Class A Common Stock 0 $7.25 Direct F6
holding RXRX Stock Option (Right to Buy) 666,898 19 Dec 2025 Class A Common Stock 0 $10.09 Direct F7
holding RXRX Stock Option (Right to Buy) 813,600 19 Dec 2025 Class A Common Stock 0 $8.55 Direct F8
holding RXRX Stock Option (Right to Buy) 399,002 19 Dec 2025 Class A Common Stock 0 $11.4 Direct F9
holding RXRX Stock Option (Right to Buy) 5,436 19 Dec 2025 Class A Common Stock 0 $11.4 Direct
holding RXRX Stock Option (Right to Buy) 282,500 19 Dec 2025 Class A Common Stock 0 $2.48 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F2 This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
F3 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F4 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F5 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F7 The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F8 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9 The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10 The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.